Elysia 1A
Solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals (equipment / SW / services).
€56,650
total amount raised in round
- Backed by over 100 investors
This campaign has been closed
DISCLAIMER
Every investment decision must be based on an examination of an exhaustive set of information provided by the entrepreneur on their online profile. Spreds only proceeds to a limited verification of this information and does not control the investment opportunity within this company. Spreds did not verify the extent to which the business plan is deemed realistic and does not intervene in determining the final terms of the investment, including the retained maximum valuation. Spreds will align itself with the financial terms negotiated with the co-investor(s).
Description
Elysia, your partner to ensure radio-pharmaceuticals quality to fight more effectively against cancer in the world.
The project is the development of an integrated solution for dedicated quality control laboratories for the production of RP (drugs for diagnostic purposes such as PET and SPECT imaging or for therapeutic purposes).
This solution is completely modular, fully integrated with a simple use and applicable to different RP.
The solution should integrate the three pillars; hardware, software, and services.
The company is being created.
We established contact with potential customers who seem very interested in the solution offered and who are waiting for the laboratory test to be functional to come visit.
If we can complete this laboratory test within 8 months, we are assured of a first order this year.
We established contact with potential customers who seem very interested in the solution offered and who are waiting for the laboratory test to be functional to come visit.
If we can complete this laboratory test within 8 months, we are assured of a first order this year.
Problem
The project stems from an absence of an integrated quality control (QC) solution for radiopharmaceutical products (RP) laboratories. This fact has been observed by many practitioners in the field and confirmed by one of the project leaders (Daniel Bartholemy). Therefore he intends to leverage its experience in the RP production to develop a comprehensive and innovative solution.
Idea
1) Sales through original equipment manufacturers (i.e. for important production centres or cyclotrons). The latter, having contact with the end customer, become QC2GO customers and integrate the solution into their own product offer.
2) Direct sales to producers of FDG (Fluorodeoxyglucose) such as CisBio, Cyclopharma, PETNET or AAA.
3) Direct sales to decentralised laboratories and nuclear medicine departments.
2) Direct sales to producers of FDG (Fluorodeoxyglucose) such as CisBio, Cyclopharma, PETNET or AAA.
3) Direct sales to decentralised laboratories and nuclear medicine departments.